CCR1 and central nervous system cancer: One of the limitations of the present study is that we cannot definitively claim it is CCR1 on TAMs, as opposed to the GL261 glioma cells which is mediating invasion, since we are using pharmacological inhibition to globally inhibit CCR1 activity.